目的 观察孟鲁司特钠咀嚼片联合枸地氯雷他定片治疗慢性荨麻疹患者的临床疗效及安全性.方法 将慢性荨麻疹患者按队列法分为对照组和试验组.对照组给予孟鲁司特钠咀嚼片每晚10 mg,口服咀嚼;试验组在对照组治疗的基础上,联用枸地氯雷他定片每次8.8 mg,qd,口服.2组患者均治疗4周.比较2组患者的临床疗效,血清免疫球蛋白E(IgE)、白细胞介素-4(IL-4)和干扰素-γ(INF-γ)水平,以及药物不良反应的发生情况.结果 试验组和对照组分别入组68和66例.治疗后,试验组和对照组的总有效率分别为95.59％(65例/68例)和83.33％(55例/66例),在统计学上差异有统计学意义(P＜0.05).治疗后,试验组和对照组的IgE分别为(70.55±8.50)和(92.57±9.65)U·mL-1,IL-4 分别为(6.87±1.35)和(8.49±1.23)pg·mL-1,INF-γ分别为(23.24±6.87)和(19.83±6.75)pg·mL-1,在统计学上差异均有统计学意义(均P＜0.05).试验组的药物不良反应主要有嗜睡、乏力,对照组的药物不良反应主要是嗜睡、乏力.试验组和对照组的总药物不良反应发生率分别为8.82％和4.55％,在统计学上差异无统计学意义(P＞0.05).结论 孟鲁司特钠咀嚼片联合枸地氯雷他定片治疗慢性荨麻疹患者的临床效果显著,其能有效调控细胞血清IgE、IL-4和INF-γ水平,且不增加药物不良反应的发生率.
Objective To observe the clinical efficacy and safety of montelukast sodium chewable tablets combined with desloratadine citrate disodium tablets in the treatment of patients with chronic urticaria.Methods Patients with chronic urticaria were divided into control group and treatment group according to cohort method.Control group was treated with montelukast sodium chewable tablets 10 mg per night,orally chewed.On the basis of control group,the treatment group was treated with desloratadine citrate disodium tablets 8.8 mg each time,qd,orally.Two groups of patients were treated for 4 weeks.The clinical efficacy,serum levels of immunoglobulin E(IgE),interleukin-4(IL-4)and interferon-γ(INF-γ),and adverse drug reactions were compared between two groups.Results The treatment group and control group were enrolled with 68 and 66 cases,respectively.After treatment,the total effective rates of treatment and control groups were 95.59％(65 cases/68 cases)and 83.33％(55 cases/66 cases)with significant difference(P＜0.05).After treatment,the IgE levels of treatment and control groups were(70.55±8.50)and(92.57±9.65)U·mL-1;the IL-4 levels were(6.87±1.35)and(8.49±1.23)pg·mL-1;the INF-γ levels were(23.24±6.87)and(19.83±6.75)pg·mL-1;the differences were statistically significant(all P＜0.05).The adverse drug reactions of treatment group were drowsiness and fatigue,while those in the control group were drowsiness and fatigue.The total incidences of adverse drug reactions in the treatment and control groups were 8.82％and 4.55％without significant difference(P＞0.05).Conclusion Montelukast sodium chewable tablets combined with desloratadine citrate disodium tablets have a definitive clinical efficacy in the treatment of patients with chronic urticaria,which can effectively regulate the serum levels of IgE,IL-4 and INF-γ,without increasing the incidence of adverse reactions.
任翠华;卢正文;盛浩;徐章
武汉市普仁医院皮肤科,湖北武汉 430080重庆大学附属肿瘤医院丰都分院超声科,重庆 408200
药学
孟鲁司特钠咀嚼片;枸地氯雷他定片;慢性荨麻疹;临床疗效;安全性评价
montelukast sodium chewable tablet;desloratadine citrate disodium tablet;chronic urticaria;clinical efficacy;safety evaluation
《中国临床药理学杂志》 2024 (005)
659-662 / 4
10.13699/j.cnki.1001-6821.2024.05.006
评论